Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) – Stock analysts at SunTrust Banks cut their FY2018 earnings per share estimates for shares of Dicerna Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 6th. SunTrust Banks analyst E. Nash now expects that the biopharmaceutical company will post earnings of ($1.21) per share for the year, down from their previous estimate of ($1.09). SunTrust Banks has a “Buy” rating and a $20.00 price objective on the stock. SunTrust Banks also issued estimates for Dicerna Pharmaceuticals’ Q4 2018 earnings at ($0.31) EPS, Q2 2019 earnings at ($0.28) EPS, FY2019 earnings at ($1.19) EPS, FY2020 earnings at ($1.07) EPS, FY2021 earnings at ($1.07) EPS and FY2022 earnings at ($0.78) EPS.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.11). The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.67 million. Dicerna Pharmaceuticals had a negative net margin of 1,418.01% and a negative return on equity of 63.24%.
DRNA stock opened at $14.72 on Friday. Dicerna Pharmaceuticals has a 52-week low of $6.80 and a 52-week high of $17.98. The stock has a market cap of $900.20 million, a price-to-earnings ratio of -4.02 and a beta of 2.37.
In other news, Director Brian K. Halak sold 335,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $13.33, for a total value of $4,465,550.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Brian K. Halak sold 564,300 shares of the business’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $13.66, for a total value of $7,708,338.00. The disclosure for this sale can be found here. Insiders sold a total of 1,161,228 shares of company stock worth $15,858,388 in the last 90 days. Company insiders own 19.85% of the company’s stock.
Several large investors have recently bought and sold shares of DRNA. Northern Trust Corp raised its holdings in shares of Dicerna Pharmaceuticals by 63.7% in the 1st quarter. Northern Trust Corp now owns 59,384 shares of the biopharmaceutical company’s stock worth $568,000 after purchasing an additional 23,102 shares during the period. BlackRock Inc. raised its holdings in shares of Dicerna Pharmaceuticals by 136.5% in the 1st quarter. BlackRock Inc. now owns 277,493 shares of the biopharmaceutical company’s stock worth $2,652,000 after purchasing an additional 160,172 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Dicerna Pharmaceuticals by 241.4% in the 1st quarter. JPMorgan Chase & Co. now owns 120,948 shares of the biopharmaceutical company’s stock worth $1,156,000 after purchasing an additional 85,525 shares during the period. Jane Street Group LLC bought a new stake in shares of Dicerna Pharmaceuticals in the 1st quarter worth approximately $136,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Dicerna Pharmaceuticals in the 1st quarter worth approximately $102,000. 74.46% of the stock is currently owned by institutional investors.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Featured Article: Stock Symbol
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.